Soon-Shiong becomes executive chairman of NantKwest’s board and retains roughly two-thirds ownership of the company with more than 67 million shares.
Soon-Shiong remains chief executive of ImmunityBio, a privately held company that has worked with NantKwest to develop immune system-based drugs to combat a range of diseases, including cancer and, more recently, Covid-19.